[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv
| Quartal / Datum | EPS (USD) | Schätzung (USD) | Abweichung |
|---|
| Quartal / Datum | Umsatz (Mrd USD) | Schätzung (Mrd USD) | Abweichung |
|---|